Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.28 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The firm had revenue of $277.86 million during the quarter.
Bavarian Nordic Trading Down 1.1%
Shares of BVNRY traded down $0.13 during midday trading on Friday, hitting $11.68. 326 shares of the company’s stock traded hands, compared to its average volume of 2,944. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 11.80 and a beta of 1.33. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $12.72. The firm’s fifty day moving average is $11.49 and its 200-day moving average is $10.21.
Bavarian Nordic Company Profile
Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.
Read More
- Five stocks we like better than Bavarian Nordic
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
